DEEP RESEARCH · Inventage Lab

Inventage Lab (389470) — Becoming Boehringer's Microfluidics Partner

A Korean LAI platform earns 'Global Pharma-grade' validation through Boehringer Ingelheim — a diagnosis of tech, pipeline, and financials.

Published: 2025-11-21 · Lens: Platform validation event and pipeline re-rating · Source: Naver Blog original

0. Bottom line first

• Event (2025-11-21): Definitive co-development contract with Boehringer Ingelheim for a long-acting injectable (LAI) — beyond exploration/MTA, covering clinical development and commercialization.
• Moat: Instead of scaling up a single channel, Inventage numbers up channels — preserving particle uniformity (CV < 5%) at commercial scale.
• Market: Global LAI market ~$19.14B (2025) → ~$57.26B (2034), CAGR ~13%. Peptide therapeutics market: ~$49.7B → ~$100B over the same period.
• Risks: Ongoing operating losses, CB/BW overhang, and potential mark-to-market loss from related-party Quratis.

1. Introduction — A biotech quantum leap

On November 21, 2025, Drug Delivery System (DDS) specialist Inventage Lab (389470.KQ) disclosed a co-development contract for a Long-Acting Injectable (LAI) with Germany's Boehringer Ingelheim. The deal goes beyond exploration or material transfer — it covers clinical development and commercialization, signaling that the company's proprietary microfluidics platform IVL-DrugFluidic® has cleared the toughest QC bars in global pharma.

Over the past several years, pharma has shifted from small molecules toward peptides, proteins, and gene therapies. These high-potency drugs have powerful effects but short half-lives and low bioavailability — and daily injections sap adherence. Inventage attacks this unmet need with precise control over in-vivo release kinetics.

2. Industry — DDS evolution and market opportunity

2.1 Structural growth of the LAI market

Official fact: Market research forecasts global LAI of ~$19.14B in 2025 → ~$57.26B by 2034, ~13% CAGR (Precedence Research, Verified Market Research).

Interpretation: Chronic disease growth, aging populations, and a patient-centric paradigm push LAIs from niche to mainstream. In schizophrenia, Alzheimer's, and addiction — diseases where self-adherence is intrinsically low — monthly or multi-month dosing becomes the new standard.

2.2 Peptide drug boom and the delivery bottleneck

With GLP-1 obesity/diabetes drugs in the spotlight, the peptide therapeutics market is projected to grow from ~$49.7B in 2025 to ~$100B by 2034 (GMI, Grand View). Peptides are rapidly degraded by enzymes, severely limiting duration of action; PEGylation only stretches dosing to weekly. Biodegradable polymer (e.g., PLGA) microsphere technology can extend dosing to ≥1 month, which is exactly why Boehringer partnered with Inventage to maximize the value of its peptide pipeline.

2.3 Manufacturing paradigm shift — Batch → Continuous

3. Platform technology deep dive

Inventage's enterprise value rests on an extensible platform applicable to many molecules, not the success of any single pipeline.

3.1 IVL-DrugFluidic® — Precision-controlled drug delivery

• Mechanism: Two immiscible fluids (polymer-oil phase + drug-aqueous phase) flow through microchannels; interfacial tension is precisely tuned under laminar flow to form uniform droplets, like water dripping from a faucet. Solvent removal and solidification produce microspheres.
• Edge ①: Initial burst suppression — Smooth surface and dense internal structure suppress early release, essential for drugs with narrow therapeutic windows (Alzheimer's, hormones).
• Edge ②: Scale-up solved — Instead of widening a single channel, Inventage uses numbering-up (more channels), preserving lab-grade quality at commercial scale. That reproducibility is gold in licensing deals.

3.2 IVL-GeneFluidic® — Gene therapy manufacturing

• High encapsulation, high yield: Tight control of mRNA/lipid flow ratios delivers 95–98% encapsulation efficiency, minimizing waste of expensive mRNA.
• CDMO expansion: Reaches into cell and gene therapy (CGT). The LNP CDMO JV with EuBiologics formalizes a stable cash model that offsets pipeline risk.

3.3 Next-gen — Oral peptides (IVL-PePOFluidic) and LNP

Beyond injectables, Inventage is developing IVL-PePOFluidic for oral peptides — shielding peptides from gastric degradation and boosting intestinal absorption, aimed squarely at the oral obesity drug market that global pharma is racing to win.

4. Boehringer partnership — The quantum-leap trigger

4.1 Contract details and trajectory

Official fact: Initial joint research began in H2 2023 → September 2024 saw an agreement beyond an MTA → November 21, 2025 brought the definitive co-development contract (Daily Pharm Korea, TheBioNews).

Structurally, Boehringer provides its proprietary peptide candidate; Inventage formulates it into an LAI via IVL-DrugFluidic® and handles preclinical/clinical material production. Boehringer leads global clinical development and commercialization, with Inventage supplying manufacturing know-how or direct production.

4.2 Boehringer's strategic intent

Interpretation: Boehringer is doubling down on obesity/metabolic disease (e.g., the glucagon/GLP-1 dual agonist Survodutide). Although the target molecule isn't disclosed, the market suspects a peptide-based obesity drug. A monthly-dose option against daily/weekly competitors would be a category-shifting weapon.

4.3 Comparative edge vs. G2G Bio

Boehringer also signed a similar co-development deal with G2G Bio — a multi-vendor hedge. Even so, Inventage stands out for its pure microfluidics approach. G2G's 'InnoLAMP' (microfluidic + membrane emulsification hybrid) is solid, but Inventage's tech is widely seen as superior on particle uniformity and QC.

5. Key pipelines — Clinical data and commercialization

5.1 Hair loss — IVL3001 / IVL3002 (game changer)

• IVL3001 (1-month finasteride): Australian Phase 1 showed hair-growth efficacy comparable to oral Propecia with a steadier blood drug profile. DHT suppression matched oral while reducing systemic exposure variability — lower side-effect risk. Daewoong/Withus partnership sets up domestic launch.
• IVL3002 (3-month finasteride): Premium line extending dosing to quarterly. Preclinical / early-clinical.

5.2 Alzheimer's — IVL3003 (adherence revolution)

Oral donepezil causes frequent GI side effects, and dementia patients often miss doses. IVL3003 is a monthly LAI that bypasses the GI tract and, in Australian Phase 1/2, showed a PK profile that suppresses initial burst and maintains effective concentration over a month — solving the toxicity issue rivals have struggled with.

5.3 Addiction — IVL3004

A naltrexone-based LAI for alcohol/opioid dependence. The opioid crisis is a US national emergency, and a once-monthly injection that prevents arbitrary discontinuation could be a major US asset. Australian Phase 1 is ongoing.

[Table 1] Inventage Lab key pipelines

6. Financials and risk

6.1 Financials — Investment phase

• Revenue mix: Product revenue is minimal; licensing milestones and services dominate. The Boehringer collaboration drove YoY revenue growth into 2024 (financial summary).
• Operating loss: Continues, driven by aggressive R&D — a necessary stage for pipeline value buildup.
• Cash flow: Operating CF is negative, but cash on hand can sustain the current burn rate for a while.

6.2 Funding and overhang

Interpretation: CB/BW issuances create latent supply. With rising share price, conversion is more likely than the put-option exercise, reducing immediate cash drain. Watch the related-party Quratis investment — it could create mark-to-market volatility in non-operating income.

7. Competitive landscape — Peptron vs. G2G Bio vs. Inventage Lab

[Table 2] Korean LAI platform players

Peptron's PT105 has cleared market validation, while G2G's InnoLAMP claims 60%+ drug loading.

8. Outlook and investment view

8.1 Roadmap into 2026 and beyond

• Short term (6–12 months): Boehringer project milestones; IVL3001 NDA filing in Korea; further global L/O discussions — catalysts.
• Medium term (2–3 years): IVL-GeneFluidic® LNP CDMO ramp; visibility on oral peptide (IVL-PePOFluidic) → second leg in obesity.

8.2 Investment view